Literature DB >> 15456350

Distribution of Candida species in different clinical sources in Delhi, India, and proteinase and phospholipase activity of Candida albicans isolates.

Somansu Basu1, Harish C Gugnani, Sangeeta Joshi, Neera Gupta.   

Abstract

Eighty-five isolates of Candida recovered from three hundred and fifty diverse clinical sources, viz. respiratory tract (sputum, bronchial washing,bronchoalveolar lavage, tracheal aspirate), blood, urine, high vaginal swab, skin and plastic devices, were studied in detail for their morphological and biochemical characters. Seven species of Candida were identified, viz., C. albicans (45.8%), C. tropicalis (24.7%), C. parapsilosis (10.5%), C. krusei (7.0%), C. kefyr (7.0%), C. guilliermondii (3.5%), and C. glabrata (1.1%). C. albicans was the predominant species isolated from all clinical specimens, except blood from which C. krusei was most frequently (38.4%) recovered. Out of 39 isolates of C. albicans, 26 (66.6%) and 19 (48.7%) exhibited strong proteinase and phospholipase activity respectively. There was a higher prevalence of proteinase producing strains amongst the vaginal and skin isolates than that in urinary and respiratory isolates. Also a greater number of phospholipase producing strains was observed in the vaginal and urinary isolates than that in the respiratory and skin isolates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15456350

Source DB:  PubMed          Journal:  Rev Iberoam Micol        ISSN: 1130-1406            Impact factor:   1.044


  9 in total

Review 1.  Insights into Candida tropicalis nosocomial infections and virulence factors.

Authors:  M Negri; S Silva; M Henriques; R Oliveira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-30       Impact factor: 3.267

2.  Acid proteinase, phospholipase, and biofilm production of Candida species isolated from blood cultures.

Authors:  Gulce Gokce; Nilgun Cerikcioglu; Aysegul Yagci
Journal:  Mycopathologia       Date:  2007-09-15       Impact factor: 2.574

3.  Phospholipase and proteinase activities of clinical isolates of Candida from immunocompromised patients.

Authors:  C P Girish Kumar; S Suresh Jothi Kumar; Thangam Menon
Journal:  Mycopathologia       Date:  2006-04       Impact factor: 2.574

4.  The First Reported Case of Colonic Infection Caused by Candida tropicalis and a Review of the Literature.

Authors:  Surat Praneenararat
Journal:  Case Rep Gastroenterol       Date:  2014-06-04

5.  Evaluation of Virulence Factors In vitro, Resistance to Osmotic Stress and Antifungal Susceptibility of Candida tropicalis Isolated from the Coastal Environment of Northeast Brazil.

Authors:  Diana L Zuza-Alves; Sayama S T Q de Medeiros; Luanda B F C de Souza; Walicyranison P Silva-Rocha; Elaine C Francisco; Maria C B de Araújo; Reginaldo G Lima-Neto; Rejane P Neves; Analy S de Azevedo Melo; Guilherme M Chaves
Journal:  Front Microbiol       Date:  2016-11-15       Impact factor: 5.640

Review 6.  An Update on Candida tropicalis Based on Basic and Clinical Approaches.

Authors:  Diana L Zuza-Alves; Walicyranison P Silva-Rocha; Guilherme M Chaves
Journal:  Front Microbiol       Date:  2017-10-13       Impact factor: 5.640

7.  Selection and evaluation of appropriate reference genes for RT-qPCR based expression analysis in Candida tropicalis following azole treatment.

Authors:  Saikat Paul; Shreya Singh; Arunaloke Chakrabarti; Shivaprakash M Rudramurthy; Anup K Ghosh
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

8.  Distribution of Pathogenic Yeasts in Different Clinical Samples: Their Identification, Antifungal Susceptibility Pattern, and Cell Invasion Assays.

Authors:  Satish T Pote; Mahesh S Sonawane; Praveen Rahi; Sunil R Shah; Yogesh S Shouche; Milind S Patole; Madhuri R Thakar; Rohit Sharma
Journal:  Infect Drug Resist       Date:  2020-04-20       Impact factor: 4.003

9.  Endogenous fungal endopthalmitis treated with intravitreal caspofungin in a COVID-19 recovered patient: A case report.

Authors:  Chinmay Nakhwa
Journal:  Indian J Ophthalmol       Date:  2021-12       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.